NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis $2.75 -0.21 (-7.09%) (As of 02:20 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Galmed Pharmaceuticals Stock (NASDAQ:GLMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galmed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.75▼$2.9450-Day Range$2.88▼$15.1052-Week Range$2.73▼$23.80Volume41,791 shsAverage Volume759,034 shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGalmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Read More… Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Galmed Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks24th Percentile Overall ScoreGLMD MarketRank™: Galmed Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Galmed Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Galmed Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galmed Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalmed Pharmaceuticals has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galmed Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.08% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently increased by 73.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalmed Pharmaceuticals does not currently pay a dividend.Dividend GrowthGalmed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.08% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently increased by 73.86%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News SentimentN/A News SentimentGalmed Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.Search Interest2 people have searched for GLMD on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Galmed Pharmaceuticals' insider trading history. Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address GLMD Stock News HeadlinesGalmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?November 14, 2024 | americanbankingnews.comGalmed Pharmaceuticals Amends Equity Purchase AgreementOctober 23, 2024 | markets.businessinsider.comNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.November 21, 2024 | Darwin (Ad)Galmed publishes Results from Aramchol Phase 3 Open Label part in HepatologySeptember 25, 2024 | prnewswire.comBenzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About YetSeptember 20, 2024 | benzinga.comGalmed Pharmaceuticals Stock Is Soaring Thursday: Here's WhySeptember 19, 2024 | msn.comGalmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesSeptember 19, 2024 | prnewswire.comGalmed Pharmaceuticals (NASDAQ:GLMD) Stock, Short Interest ReportSeptember 19, 2024 | benzinga.comSee More Headlines GLMD Stock Analysis - Frequently Asked Questions How have GLMD shares performed this year? Galmed Pharmaceuticals' stock was trading at $5.46 at the beginning of the year. Since then, GLMD shares have decreased by 47.1% and is now trading at $2.89. View the best growth stocks for 2024 here. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its earnings results on Wednesday, August, 28th. The biopharmaceutical company reported $2.16 EPS for the quarter. When did Galmed Pharmaceuticals' stock split? Galmed Pharmaceuticals shares reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol-Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/28/2024Today11/21/2024Next Earnings (Estimated)11/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($16.6561) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.75% Return on Assets-24.98% Debt Debt-to-Equity RatioN/A Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$28.64 per share Price / Book0.10Miscellaneous Outstanding Shares640,000Free Float516,000Market Cap$1.89 million OptionableNot Optionable Beta0.80 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:GLMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.